Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CACNA1G
REST API REST API
Homo sapiens
CACNA1G is differentially expressed in 242 experiments: 168 organism parts: cerebellum, hypothalamus, ... (166 more);, 226 disease states: normal, "AIDS-KS, HIV+, nodular (late) stage", ... (224 more);, 64 cell types 288 cell lines 27 compound treatments and 74 other conditions.
Synonyms NBR13, Cav3.1
Orthologs F1NKQ9_CHICK (Gallus gallus)   Cacna1g (Mus musculus)   cacna1g (Danio rerio)   CACNA1G (Bos taurus)   ENSCING00000004031 (Ciona intestinalis)   Cacna1g (Rattus norvegicus)   cacna1g (Xenopus laevis)   CACNA1G (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, transport, regulation of heart rate, ion transport, membrane, ion channel activity, voltage-gated calcium channel activity, axon guidance, synaptic transmission, voltage-gated ion channel activity, integral to membrane, transmembrane transport, calcium ion transport, voltage-gated calcium channel complex, response to nickel ion, low voltage-gated calcium channel activity, regulation of calcium ion transport via voltage-gated calcium channel activity, regulation of atrial cardiomyocyte membrane depolarization
InterPro Term VDCC_T_a1su, VDCCAlpha1, PKD1_2_channel, Ion_trans
UniProt Accession Q2TAC4, Q19QZ7, Q19QZ6, Q19QZ9, Q19QZ8, Q19QZ3, Q19QZ2, Q19QZ5, Q19QZ4, Q19QY9, Q19QY8, Q19QZ0, Q19QZ1, Q19R18, Q19R17, Q19R16, Q19R15, Q19R13, Q19R12, Q19R11, Q19R10, Q19R09, Q19R06, Q19R05, Q19R08, Q19R07, Q19R02, Q19R01, Q19R04, Q19R03, Q19R00, O43497
Search EB-eye ENSG00000006283
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, E-GEOD-4219, ... (26 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
HL-60
3
E-GEOD-24147, E-MTAB-37, E-GEOD-5258
A549
3
2
E-GEOD-6013, E-GEOD-3202
primary culture
2
E-GEOD-2450, E-GEOD-1657
MCF-7
1
2
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
REC
1
E-MTAB-62
282 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, E-GEOD-13987, ... (35 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3920, E-GEOD-26672, E-GEOD-3204
CD34+
2
E-TABM-145, E-AFMX-5
testis - germ cell
1
E-AFMX-5
CD326negCD56+ cell
1
E-GEOD-21668
BDCA1+ dendritic cell
1
1
E-TABM-34
activated natural killer cell (supplemented for IL2 for 2 hours)
1
E-TABM-702
58 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-16363, E-MTAB-680, ... (49 experiments)

Factor Value U/D Experiments
Emery-Dreifuss muscular dystrophy
2
E-GEOD-3307, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
220 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-6907, E-GEOD-5824, E-GEOD-3720, ... (19 experiments)

Factor Value U/D Experiments
none
1
6
E-GEOD-412, E-GEOD-5824, E-GEOD-2803, E-GEOD-1615, E-MEXP-1269, ... (7 experiments)
glutamine
2
E-MEXP-1335, E-MEXP-941
rapamycin
1
E-GEOD-5824
valproic acid
1
E-GEOD-1615
cigarette smoke
2
1
E-TABM-127
no estradiol
1
E-GEOD-20081
21 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
38
2
1
E-GEOD-21653


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-6236, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-GEOD-21138, E-GEOD-1751 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-MTAB-108, E-GEOD-4006

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-TABM-601, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-12773, E-TABM-127, E-GEOD-20540, E-GEOD-9764, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-GEOD-974, E-GEOD-1926, E-MEXP-2069, E-TABM-15, ... (28 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (7 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-GEOD-3485

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-7307, E-GEOD-21521

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271

Tumor size
studied in E-GEOD-8167

Processing time: 0.498 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM